

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

## **VOLUNTARY ANNOUNCEMENT**

### **PRE-APPLICATION FOR CLINICAL TRIALS FOR NOVEL-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE SUBMITTED**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24, 2024. Currently, there is a lack of effective clinical treatment for rabies, and therefore post exposure prevention is crucial. The main preventive measures are inoculation of human rabies vaccine and injection of passive immunization agents. The human diploid cell rabies vaccine has natural safety advantages and a broad market space.

The novel-process highly-effective human diploid rabies vaccine developed by the Group became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.

The Group has completed the construction of its workshop for novel-process highly-effective human diploid rabies vaccine, which has sufficient production capacity and meets international standards, and the equipment is currently being debugged and verified. As the second largest supplier of rabies vaccines globally, the Group spearheads the in-depth technological iteration of rabies vaccines in the world, and will deliver rabies vaccine products with better quality and higher safety in the market after the iterative rabies series vaccines are marketed, so that new productive forces will be achieved in the industry.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 26, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*